Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Vanda Pharmaceuticals clinical trials
The registry lists 82 studies whose lead sponsor is Vanda Pharmaceuticals. 17 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Vanda Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Vanda Pharmaceuticals.
- Vanda Pharmaceuticals82 studiesSame company
Something wrong?
Focus areas
Conditions Vanda Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 82. Browse all 82 →
- Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsRecruitingNCT05648591Phase 4
- Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderRecruitingNCT06830044Phase 3
- Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque PsoriasisRecruitingNCT07362017Phase 3
- Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative ColitisRecruitingNCT07686081Phase 3
- Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric InsomniaRecruitingNCT06953869Phase 3
- A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseRecruitingNCT07446439Phase 3
- Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT03838926Phase 1
- Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionRecruitingNCT07090161Phase 2
- Randomized Withdrawal Study in Patients With SchizophreniaRecruitingNCT06961968Phase 3
- An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeRecruitingNCT07179055Phase 2
- Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With GastroparesisAvailableNCT04474990
- Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 VariantRecruitingNCT06701396Phase 3
- Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep DisturbancesRecruitingNCT05361707Phase 3
- Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep DisturbancesRecruitingNCT03154697
- A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeRecruitingNCT06296966Phase 2
- Patient Registry of Blind Subjects With Sleep-related ProblemsRecruitingNCT01195558
- ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionEnrolling by invitationNCT04326426Phase 3
- Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisCompletedNCT06836557Phase 3
- Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)CompletedNCT04652882Phase 3
- Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute SchizophreniaCompletedNCT00254202Phase 3
- Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic GastroparesisCompletedNCT04028492Phase 3
- Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual PatientActive, not recruitingNCT07223632Phase 1/2
- Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety DisorderActive, not recruitingNCT07221578Phase 3
- Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessActive, not recruitingNCT06138613Phase 3
- Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPTerminatedNCT05366855Phase 3
- Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPCompletedNCT05352893Phase 3
- Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisActive, not recruitingNCT07065773Phase 2
- A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist UseCompletedNCT06804603Phase 2
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis SuppurativaCompletedNCT04856930Phase 2
- A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform RashTerminatedNCT04697069Phase 2
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne VulgarisCompletedNCT04856917Phase 2
- Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsCompletedNCT06494397Phase 1
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular PsoriasisCompletedNCT03619902Phase 2
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With IchthyosisTerminatedNCT04697056Phase 2
- A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar PustulosisCompletedNCT03633396Phase 2
- Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular AllergiesCompletedNCT04622345Phase 2
- Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedNCT03772340Phase 2
- Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessCompletedNCT05903924Phase 3
- Food Effect Study of VHX-896 in Healthy VolunteersCompletedNCT06803290Phase 1
- Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion SicknessCompletedNCT04327661Phase 3
- Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of GastroparesisCompletedNCT02970968Phase 2
- Tradipitant in Treatment-resistant Pruritus Associated With Atopic DermatitisCompletedNCT02651714Phase 2
- Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic DermatitisCompletedNCT02004041Phase 2
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)TerminatedNCT04140695Phase 3
- Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)CompletedNCT03568331Phase 3
- Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I DisorderCompletedNCT04819776Phase 3
- Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy VolunteersCompletedNCT04849559Phase 1/2
- Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light PerceptionActive, not recruitingNCT01218789Phase 3
- WGS Analysis of COVID-19 Positive PatientsCompletedNCT04353401
- A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease PsychosisWithdrawnNCT05344365Phase 2